On November 13, 2026, the Food and Drug Administration approved durvalumab in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment after radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC) who are ineligible for or who have refused cisplatin based chemotherapy.
Full prescribing information for durvalumab will be posted on Drugs@FDA.
Efficacy and Safety
Efficacy was evaluated in VOLGA (NCT04960709), a randomized, open-label trial. The trial randomized (1:1:1) 695 patients with MIBC who were candidates for radical cystectomy (RC) and who were ineligible for or who refused cisplatin-based chemotherapy to receive neoadjuvant durvalumab and enfortumab vedotin-ejfv prior to surgery followed by adjuvant durvalumab, RC alone, or an additional investigational combination regimen.
The major efficacy outcome measure was event-free survival (EFS) by blinded independent central review assessment. Overall survival (OS) was an additional efficacy outcome measure.
The trial demonstrated statistically significant improvements in both EFS and OS for durvalumab/enfortumab vedotin-ejfv compared to RC alone. Median EFS was not reached (NR) (95% CI: 33.2, NR) in the durvalumab/enfortumab vedotin-ejfv arm and was 12.1 months (95% CI: 7.6, 27.0) in the RC alone arm (hazard ratio 0.51 [95% CI: 0.38, 0.67]; two-sided p-value < 0.0001). Median OS was not reached in either the durvalumab/enfortumab vedotin-ejfv arm or the RC alone arm (hazard ratio 0.58 [95% CI: 0.40, 0.83]; two-sided p-value 0.0027).
The durvalumab prescribing information includes warnings and precautions for immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation, and embryo-fetal toxicities.
The most common adverse reactions (> 20%), including laboratory abnormalities, for durvalumab in combination with enfortumab vedotin-ejfv were increased AST, increased ALT, decreased hemoglobin, rash, increased creatinine, pruritus, decreased calcium, increased lipase, increased potassium, urinary tract infection, increased amylase, fatigue, decreased sodium, decreased lymphocytes, diarrhea, decreased leukocytes, constipation, decreased appetite, increased alkaline phosphatase, dysgeusia, nausea, peripheral neuropathy, musculoskeletal pain, and alopecia.
Recommended Dosage
The recommended durvalumab dose for patients with a body weight of ≥30 kg is 1,500 mg every 3 weeks in combination with neoadjuvant enfortumab vedotin-ejfv 1.25 mg/kg (on Days 1 and 8 of each cycle) for 3 cycles prior to surgery, followed by durvalumab 1,500 mg as a single agent every 4 weeks for up to 9 cycles after surgery. The recommended durvalumab dose for patients with a body weight <30 kg is 20 mg/kg every 3 weeks in combination with neoadjuvant enfortumab vedotin-ejfv 1.25 mg/kg (on Days 1 and 8 of each cycle) for 3 cycles prior to surgery, followed by durvalumab 20 mg/kg every 4 weeks as a single agent for up to 9 cycles after surgery. Treatment should continue until disease progression that precludes definitive surgery, recurrence, or unacceptable toxicity, or a maximum of 9 cycles after surgery.
This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration (TGA), the Brazilian Health Regulatory Agency (ANVISA), Health Canada, Israel’s Ministry of Health (IMoH), Singapore’s Health Sciences Authority (HSA), and the United Kingdon’s Medicines and Healthcare products Regulatory Agency (MHRA). The applications may be undergoing the submission process or still be under review at the other regulatory agencies.
This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application six weeks ahead of the FDA goal date.
This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.
For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov
Source: FDA
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.